Genzyme Convenes Sixth Annual Gaucher Leadership Forum
March 26 2015 - 1:30PM
Business Wire
- Forum provides platform for discussion on
current and future care of patients living with Gaucher disease
-
Genzyme, a Sanofi company, today announced that the sixth annual
Gaucher Leadership Forum (GLF) will take place on March 27 and 28
in Berlin, Germany.
The GLF is a scientific meeting sponsored by Genzyme that brings
together approximately 200 participants from around the world,
including physicians, academics, researchers and patient
organization representatives to discuss current care for patients
with Gaucher disease and the direction of future disease
management. This year’s GLF will be chaired by Timothy M. Cox,
Professor of Medicine at the University of Cambridge. The theme for
2015 is: “New Clinical Science of Gaucher Disease” and will
focus on the following objectives:
- Advancing therapeutics through greater
understanding of pathogenesis (molecular & otherwise)
- Fostering collaborative and
interdisciplinary research
- Inspiring (recruiting) the next
generation of clinician researchers and scientists
“In designing this year’s GLF program, we have sought to
encompass the hugely diverse aspects of Gaucher disease as they
impinge on the lives and well-being of patients all over the world.
It is chastening to realize that despite radical improvements over
the last 25 years, many aspects of this condition remain very hard
to treat; and even when the diagnosis eventually has come to light,
not every patient can gain access to the best standards of care,”
said Prof. Cox. “This meeting will give time for open sharing of
experience and seeks to explore under-recognized aspects of the
disease that are often neglected in the heat of routine
practice.”
The opening plenary session will highlight the most recent
scientific discoveries in the field of Gaucher disease research.
Additionally, several interactive working groups have been
established to focus on: (1) Spectrum of Clinical Manifestations in
Gaucher Disease; (2) Gaucher Disease Type 3: Addressing Patients’
and Families’ Concerns; (3) Unmet Needs in the Assessment of Bone
Disease in Gaucher; and (4) Gaucher Disease and Cancer: Mechanisms
and Management.
“The GLF is an excellent example of global collaboration and
partnership, with the Gaucher community working together to propel
research forward and further our understanding of Gaucher disease,”
said Genzyme’s Acting Head of Rare Diseases, Richard Peters, MD,
Ph.D. “While much progress has been made, great need still exists,
particularly around the neuronopathic forms of Gaucher disease. We
look forward to lively discussion while we work to achieve our
collective goal to support the needs of the global Gaucher
community.”
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of
transformative therapies for patients affected by rare and
debilitating diseases for over 30 years. We accomplish our goals
through world-class research and with the compassion and commitment
of our employees. With a focus on rare diseases and multiple
sclerosis, we are dedicated to making a positive impact on the
lives of the patients and families we serve. That goal guides and
inspires us every day. Genzyme’s portfolio of transformative
therapies, which are marketed in countries around the world,
represents groundbreaking and life-saving advances in medicine. As
a Sanofi company, Genzyme benefits from the reach and resources of
one of the world’s largest pharmaceutical companies, with a shared
commitment to improving the lives of patients. Learn more at
www.genzyme.com.
Genzyme® is a registered trademark of Genzyme Corporation. All
rights reserved.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers,
develops and distributes therapeutic solutions focused on patients’
needs. Sanofi has core strengths in the field of healthcare with
seven growth platforms: diabetes solutions, human vaccines,
innovative drugs, consumer healthcare, emerging markets, animal
health and Genzyme.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product
development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words "expects", "anticipates", "believes", "intends",
"estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
the Group's ability to benefit from external growth opportunities,
trends in exchange rates and prevailing interest rates, the impact
of cost containment policies and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under "Risk Factors" and "Cautionary
Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2014. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
Media Contact:GenzymeLori Gorski,
617-768-9344Lori.Gorski@genzyme.com
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Sep 2023 to Sep 2024